Secondary analysis of a placebo-controlled trial: in 76 immunosuppressed SSc patients vs 304 healthy controls given two RZV doses, humoral response was lower (92.6% vs 99.7%), with lower antibody GMC (5.81 vs 12.6); disease activity and PROMs stayed stable.
Secondary analysisn = 380
Luppino-Assad et al. Prospective evaluation of recombinant Herpes zoster vaccine in SSc: immunogenicity, safety and disease outcomes